Treatment Updates in Ph+ Acute Lymphoblastic Leukemia

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss current standards of care for the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.